Trending Topics in Gastroenterology | GastroAGI

RefluxStop surgery in the treatment of acid reflux

RefluxStop surgery is an innovative and highly effective procedure for the treatment of chronic gastroesophageal reflux disease (GERD), addressing the root causes of acid reflux while minimizing common side effects associated with traditional surgical approaches like Nissen fundoplication. Below is a detailed explanation of the procedure, its mechanism, clinical outcomes, and advantages: ### **Mechanism of RefluxStop Surgery** RefluxStop is designed to correct all three components of the anti-reflux barrier: 1. **Crural Diaphragm:** The procedure restores the natural anatomy by maintaining the lower esophageal sphincter (LES) below the diaphragm, reducing the risk of reflux. 2. **Lower Esophageal Sphincter (LES):** It repositions the LES to improve its function without applying external pressure or encircling it, which avoids complications like dysphagia. 3. **Gastroesophageal Flap Valve:** The surgery reconstructs the flap valve to enhance reflux resistance while preserving the natural mechanics of swallowing. Unlike fundoplication, RefluxStop avoids wrapping or compressing the esophagus and stomach, which minimizes postoperative issues such as gas-bloating and difficulty swallowing. ### **Clinical Outcomes** The RefluxStop procedure has demonstrated exceptional safety and effectiveness in a prospective multicenter study conducted over a mean follow-up period of 5.7 years. Key findings include: 1. **Symptom Relief:** - GERD symptom improvement was dramatic, with a 90% reduction in GERD-HRQL (Health-Related Quality of Life) scores. Median scores decreased from 29.5 at baseline to 3.0 at 5 years (p<0.001), indicating substantial long-term relief. 2. **Objective Acid Control:** - Esophageal acid exposure time decreased by 90.4%, from 16.35% at baseline to 1.57% at 5 years (p<0.001). This confirms durable control of acid reflux, comparable to or better than traditional surgical outcomes. 3. **PPI Discontinuation:** - At 5 years, 97.9% of patients were no longer taking daily proton pump inhibitors (PPIs). Only one patient resumed PPIs, but for unrelated kidney disease rather than reflux recurrence. 4. **Regurgitation Control:** - 93.6% of patients reported no or minimal regurgitation at 5 years, demonstrating the procedure’s ability to prevent mechanical reflux through effective LES repositioning and flap valve restoration. 5. **Device Stability:** - No instances of device migration, dislocation, erosion, or explantation were observed over the entire study period, highlighting the long-term integrity of the implant. ### **Safety Profile** The procedure has shown an excellent safety record: 1. **Adverse Events:** - Across five years, no device-related adverse events (ADEs or SADEs) occurred. Two severe postoperative complications (bleeding and infection) resolved completely without long-term consequences. 2. **Postoperative Dysphagia:** - Only one patient (2%) experienced transient mild dysphagia, which resolved within the study period. Overall, 97.9% of patients reported no dysphagia, a significant advantage over fundoplication techniques. 3. **Gastritis Symptoms:** - Eight patients experienced gastritis-related symptoms, but these were isolated and not indicative of surgical failure or reflux recurrence. ### **Comparison to Nissen Fundoplication** RefluxStop surgery offers several advantages over traditional fundoplication: 1. **Preservation of Normal Function:** - Unlike fundoplication, which causes dysphagia in nearly 29% of patients and gas-bloating in over 50%, RefluxStop preserved full ability to belch and vomit (100%) and eliminated bloating in 95.7% of patients. 2. **Minimized Complications:** - By avoiding wrapping the stomach around the esophagus, RefluxStop reduces mechanical pressure on the LES, preventing long-term esophageal complications and postoperative discomfort. ### **Durability and Long-Term Effectiveness** RefluxStop surgery has demonstrated durable results: 1. **Stable Acid Exposure:** - Acid exposure time remained low and stable between the 6-month (0.82%) and 5-year (1.57%) evaluations, confirming the mechanical and functional longevity of the anti-reflux barrier reconstruction. 2. **Quality of Life:** - Patients experienced sustained symptom relief and improved quality of life, with minimal dependence on medication. ### **Procedure-Specific Safety** RefluxStop avoids the invasive wrapping technique used in fundoplication, reducing the risk of complications like dysphagia, gas-bloating, and esophageal pressure damage. Early procedural refinements—such as ensuring proper fundic pouch tension and LES positioning—eliminated minor complications, demonstrating the reliability of the surgical technique. ### **Real-World Data Support** Independent European centers replicated the study’s findings, confirming consistent efficacy and safety across varied populations, including patients with large hiatal hernias and impaired esophageal motility. ### **Regulatory Validation** The study data were rigorously audited and independently verified by FDA consultants and third-party CROs, supporting the reliability of the safety and efficacy results. The procedure has received CE mark approval and is undergoing FDA PMA (Premarket Approval) submission. ### **Clinical Implications** RefluxStop surgery represents a paradigm shift in GERD management, offering: 1. Sustained symptom relief (>90% improvement). 2. Near-complete medication independence (97.9% off PPIs). 3. Minimal adverse effects (low dysphagia rates and no device-related complications). 4. Preservation of natural swallowing mechanics and belching ability. 5. Durable acid reflux control over the long term. This procedure has the potential to redefine the standard of care for long-term surgical correction of GERD, providing a safer and more effective alternative to traditional techniques like fundoplication.

H. Pylori Screening After Acute MI: HELP-MI SWEDEHEART Trial

The **HELP-MI SWEDEHEART trial** was a large, nationwide, cluster-randomized crossover study conducted across 35 hospitals in Sweden to evaluate whether routine screening for *Helicobacter pylori* (H. pylori) in patients hospitalized for acute myocardial infarction (MI) could reduce the risk of upper gastrointestinal (GI) bleeding, which is a common and serious complication after an MI. ### Key Details of the Trial: #### 1. **Purpose and Study Design:** - The primary aim was to determine if routine H. pylori screening and treatment in post-MI patients could lower the incidence of upper GI bleeding. - The trial utilized a **cluster-randomized crossover design** where hospitals alternated between two approaches: - **Routine screening periods**: Patients received urea breath testing for H. pylori in addition to standard care. - **Usual care periods**: Patients received only standard care without screening. - This design allowed real-world comparison of outcomes during the two periods. - The study was open-label and conducted nationwide across 18 clusters (35 hospitals). #### 2. **Study Population and Intervention:** - The trial included **18,466 patients** hospitalized with acute MI, with a median age of 71 years (71% male). - During the screening periods: - Patients underwent **urea breath testing** to detect H. pylori infection. - Of those tested, **23.6% tested positive for H. pylori**. - During the nonscreening (usual care) periods, patients were treated as per standard protocols without H. pylori testing. #### 3. **Primary Outcome: Upper GI Bleeding:** - Over a median follow-up of **1.9 years**, the incidence of upper GI bleeding was compared between the two groups: - **Screening group**: 299 patients experienced upper GI bleeding, corresponding to an incidence rate of **16.8 events per 1,000 person-years**. - **Usual care group**: 336 patients experienced upper GI bleeding, corresponding to an incidence rate of **19.2 events per 1,000 person-years**. - The **rate ratio (RR)** for upper GI bleeding was **0.90** (95% CI, 0.77–1.05; P = 0.18). - This indicates that routine H. pylori screening did not result in a **statistically significant reduction** in the risk of upper GI bleeding. #### 4. **Subgroup Findings and Heterogeneity:** - Subgroup analysis revealed that the effectiveness of H. pylori screening might vary based on the presence of anemia: - Among patients with **mild anemia**, the risk of upper GI bleeding was reduced (RR 0.64). - Among patients with **moderate-to-severe anemia**, the reduction was even greater (RR 0.44). - However, in patients **without anemia**, there was no benefit observed (RR 0.98). - The **P for interaction** was 0.03, suggesting that anemia status significantly influenced the benefit of H. pylori screening. #### 5. **Clinical Implications and Conclusion:** - **Overall Findings**: - Routine H. pylori screening after acute MI **did not significantly reduce the risk of upper GI bleeding** for the general post-MI population. - **Targeted Screening Approach**: - The subgroup analysis suggests that patients with **anemia** (especially moderate-to-severe anemia) may benefit more from H. pylori screening. - This finding highlights the potential for a **targeted screening strategy** focusing on high-risk groups, such as anemic patients, rather than universal screening for all post-MI patients. - **Conclusion**: - Routine H. pylori screening is **not recommended universally** for all post-MI patients. - A more **resource-efficient approach** could involve screening only patients at higher risk of upper GI bleeding, such as those with anemia. The trial underscores the importance of personalized medicine, where interventions are tailored to specific patient subgroups to maximize clinical benefits and minimize unnecessary resource use.

Autoimmune Gastritis related NET and Gut Microbitoa- Osaka Study

The Osaka Metropolitan University study explored the relationship between autoimmune gastritis (AIG) and the development of gastric neuroendocrine tumors (NETs), focusing on the role of gut microbiota and metabolic changes. AIG is a chronic autoimmune disorder where the immune system attacks the stomach lining, leading to tissue damage and prolonged inflammation. This inflammation is a known risk factor for NETs, tumors originating from hormone-producing cells. The study compared stomach tissue and gut microbiota profiles of AIG patients with and without NETs. AIG patients showed reduced α-diversity in gut bacteria, an indicator of poor gastric health. Distinct microbial profiles were observed between NET-positive and NET-negative groups. Harmful bacteria, such as *Haemophilus parainfluenzae* and Fusobacterium species (*F. periodonticum* and *F. nucleatum*), were elevated in NET-positive patients, while protective microbes like lactic acid bacteria and *Streptococcus salivarius* were diminished. This imbalance created a pro-inflammatory environment conducive to tumor formation. Metabolomic analysis revealed metabolic reprogramming in AIG patients, with a shift away from normal glycolysis and TCA cycles to alternative energy pathways. This disruption affected energy balance, inflammation control, and tissue repair mechanisms. The sequence of events suggested metabolic dysfunction occurred first, fostering conditions for harmful bacterial overgrowth and subsequent tumor development. The study identified microbial and metabolic biomarkers that could predict NET risk, offering potential for early diagnosis and preventive strategies. These findings underscore the combined impact of immune damage, altered metabolism, and microbiome imbalance in AIG-related cancer progression, paving the way for innovative diagnostic and therapeutic approaches.

Nonpharmacologic interventions for GERD

Nonpharmacologic interventions for gastroesophageal reflux disease (GERD) refer to therapeutic approaches that do not rely on medications but aim to improve symptoms, enhance lower esophageal sphincter (LES) function, and reduce esophageal acid exposure. These interventions can either be standalone options or used in combination with conventional therapies. Below is a detailed summary of the nonpharmacologic interventions studied, based on the provided context: --- ### **1. Acupoint Stimulation** - **Description**: Acupoint stimulation, often rooted in traditional Chinese medicine (TCM), involves stimulating specific points on the body to influence physiological functions. - **Effectiveness**: - Significantly increased LES pressure when combined with conventional or traditional Chinese medicine (Standardized Mean Difference [SMD] 3.88–7.77). - Reduced esophageal acid exposure time (SMD –2.33 to –5.01). - Improved GERD-related quality of life when used alone or in combination with other therapies. - **Safety**: - Associated with fewer adverse events compared to conventional Western therapies. - **Clinical Implication**: - Safe and effective, particularly for patients seeking culturally rooted or noninvasive options. - Offers measurable benefits as either a standalone or adjunctive therapy. --- ### **2. Breathing Training** - **Description**: Focused breathing exercises aim to strengthen the diaphragm and improve LES function. - **Effectiveness**: - Increased LES pressure when combined with conventional medicine. - Reduced esophageal acid exposure time. - **Advantages**: - Low-cost and noninvasive. - Can be easily integrated into conventional medical management. - **Clinical Implication**: - A practical and affordable adjunctive therapy for GERD patients. --- ### **3. Nissen Fundoplication** - **Description**: A surgical procedure in which the upper part of the stomach is wrapped around the LES to strengthen it and prevent acid reflux. - **Effectiveness**: - Significantly increased LES pressure (SMD 3.88–7.77). - Reduced esophageal acid exposure time (SMD –2.33 to –5.01). - **Risks**: - Higher rates of adverse events due to the invasiveness of surgery. - **Clinical Implication**: - Effective for severe or refractory GERD but may not be suitable for all patients due to surgical risks. --- ### **4. Transoral Incisionless Fundoplication (TIF)** - **Description**: A minimally invasive endoscopic procedure that creates a valve at the LES to prevent reflux. - **Effectiveness**: - Improved GERD-related quality of life. - **Advantages**: - Less invasive than traditional surgical fundoplication. - **Risks**: - Safety concerns remain, though risks are lower than with surgical fundoplication. - **Clinical Implication**: - A viable option for patients seeking minimally invasive solutions with quality-of-life benefits. --- ### **5. Integrative Approaches** - **Description**: Combining nonpharmacologic interventions with conventional medicine. - **Examples**: - **Acupoint stimulation + Traditional Chinese Medicine**: Enhanced LES pressure and reduced acid exposure time. - **Breathing training + Conventional medicine**: Additive benefits in improving LES function and acid exposure. - **Clinical Implication**: - Supports multimodal therapy tailored to individual patient needs and preferences. --- ### **6. Other Nonpharmacologic Interventions** - The analysis included a total of 11 distinct nonpharmacologic interventions across 34 randomized controlled trials (RCTs). However, specific details on all interventions were not provided in the context. --- ### **Key Findings** - **Primary Endpoint**: LES pressure was significantly improved by acupoint stimulation, breathing training, and Nissen fundoplication. - **Secondary Endpoints**: - Esophageal acid exposure time was reduced by acupoint stimulation, breathing training, and Nissen fundoplication. - GERD-related quality of life improved significantly with acupoint stimulation and transoral incisionless fundoplication. - Safety outcomes favored acupoint stimulation over more invasive interventions like fundoplication. --- ### **Safety vs. Efficacy Trade-Off** - **Acupoint Stimulation**: Emerged as both effective and safer than surgical interventions. - **Surgical Approaches**: Effective but associated with higher risks, making them suitable for severe or refractory GERD cases. - **Minimally Invasive Options**: TIF provided quality-of-life improvements with reduced invasiveness but requires careful consideration of safety. --- ### **Clinical Guidance** - **For Patients Intolerant to Medications**: Nonpharmacologic interventions provide an alternative pathway, particularly for those dissatisfied with or intolerant to long-term pharmacologic therapy. - **Personalized Care**: Clinicians should tailor therapy based on patient preferences, comorbidities, and risk tolerance. - **Adjunctive Potential**: Nonpharmacologic approaches, particularly acupoint stimulation and breathing training, can enhance outcomes when combined with conventional medicine. --- ### **Future Directions** - More high-quality, multicenter RCTs are needed to: - Validate the long-term efficacy of nonpharmacologic interventions. - Establish standardized protocols for their use in GERD treatment. --- ### **Conclusion** Nonpharmacologic interventions, particularly **acupoint stimulation** and **breathing training**, show promise as safe and effective adjunctive therapies for GERD. They offer physiological benefits (improved LES pressure, reduced acid exposure) and enhance patient-reported outcomes (quality of life). These interventions can serve as valuable alternatives or complements to conventional Western medicine, especially for patients seeking noninvasive or culturally integrated treatment options.

Bleeding risk , Blood thinners and Esophageal dilation

Esophageal dilation is a procedure used to widen a narrowed esophagus, often performed using tools such as balloon dilators or Savary dilators. While the procedure itself is generally considered low risk, the bleeding risk can increase significantly in patients using blood thinners (anticoagulants or antiplatelet agents). Below is a detailed discussion of the bleeding risk associated with blood thinners during esophageal dilation, based on the provided context: --- ### **Key Findings on Bleeding Risk** 1. **Anticoagulant Use:** - Patients on anticoagulants (e.g., warfarin, direct oral anticoagulants [DOACs] like rivaroxaban, dabigatran, apixaban, and edoxaban) had a **1.43-fold higher relative risk (RR)** of gastrointestinal (GI) bleeding within 30 days of esophageal dilation compared to nonusers. - Among anticoagulants, **warfarin** posed the highest bleeding risk, with a **1.92-fold increase in bleeding risk**. This is likely due to warfarin's narrow therapeutic index and the challenges of maintaining its optimal therapeutic range. 2. **Dual Antiplatelet Therapy (DAPT):** - Patients on DAPT (e.g., aspirin combined with ticagrelor, clopidogrel, or prasugrel) had numerically higher bleeding rates compared to nonusers or aspirin-only users. However, these differences did not reach statistical significance. - This suggests that while DAPT increases bleeding risk, the absolute risk may not be as pronounced as with anticoagulants. 3. **Aspirin Alone:** - Aspirin-only therapy was associated with a lower bleeding risk compared to DAPT, highlighting the additive bleeding risk when combining two antiplatelet agents. 4. **Timing of Antithrombotic Therapy Resumption:** - Whether anticoagulant or antiplatelet therapy was resumed early or delayed after the procedure did not significantly alter the bleeding risk. --- ### **Clinical Implications** 1. **Guideline Recommendations:** - Current guidelines recommend discontinuing anticoagulants before esophageal dilation to minimize bleeding risk, provided it is safe to do so. This is particularly important for patients on warfarin due to its higher risk profile. 2. **Thromboembolic vs. Bleeding Risk:** - For patients on blood thinners, clinicians must balance the risk of thromboembolic events (e.g., stroke or clot formation) against the risk of bleeding. This decision requires a personalized approach, often involving collaboration with cardiology or hematology specialists. 3. **Warfarin-Specific Considerations:** - Warfarin users represent a particularly high-risk group for postprocedural bleeding. These patients may require more cautious periprocedural planning, including temporary bridging with shorter-acting anticoagulants or careful INR (International Normalized Ratio) monitoring. 4. **Clinical Consequences of Bleeding:** - Postprocedural bleeding in anticoagulated patients was associated with significant clinical consequences, including higher rates of blood transfusions, ICU admissions, and even mortality. This underscores the importance of optimizing antithrombotic management before esophageal dilation. --- ### **Summary of Practice Implications** - **Anticoagulants:** - Discontinuation before esophageal dilation is generally recommended to reduce bleeding risk. - Warfarin users require extra caution due to their higher bleeding risk. - DOAC users may have a slightly lower bleeding risk compared to warfarin, but individual risk factors must still be considered. - **DAPT and Aspirin:** - DAPT increases the bleeding risk compared to aspirin alone, but the absolute risk may not always be statistically significant. - Aspirin-only therapy carries a relatively lower bleeding risk, making it a safer option in certain cases. - **Multidisciplinary Collaboration:** - Endoscopists should work closely with cardiologists and hematologists to individualize management strategies, especially for high-risk patients. - **Postprocedural Monitoring:** - Patients on anticoagulants or antiplatelets undergoing esophageal dilation should be closely monitored for signs of bleeding, given the potential for serious complications such as transfusion requirements, ICU admission, and mortality. --- ### **Conclusion** Anticoagulant use, particularly warfarin, significantly increases the risk of post-esophageal dilation bleeding. Dual antiplatelet therapy also poses a higher bleeding risk compared to aspirin alone, though the differences may not always be statistically significant. Clinicians must carefully weigh the bleeding risk against the thromboembolic risk when managing blood thinners in patients undergoing esophageal dilation, emphasizing guideline-based discontinuation of therapy whenever safely feasible. Close monitoring and individualized care are critical to optimizing outcomes.

VOYAGE trial

The **VOYAGE trial** was a **phase 2 clinical study** designed to evaluate the efficacy, safety, and tolerability of **etrasimod**, an investigational oral therapy, in adults with **eosinophilic esophagitis (EoE)**. Below is a detailed summary of the trial: --- ### **Background and Clinical Need** - **Eosinophilic Esophagitis (EoE)** is a chronic allergic inflammatory disease of the esophagus characterized by symptoms such as **dysphagia** (difficulty swallowing), **food impaction**, and **reduced quality of life**. - Current standard treatments (e.g., swallowed corticosteroids, proton pump inhibitors, and biologic therapies like dupilumab) have limitations, including **partial efficacy**, **long-term safety concerns**, and the lack of **approved oral small-molecule therapies**. - **Etrasimod** is a promising candidate for EoE treatment due to its mechanism of action as a **selective sphingosine 1-phosphate (S1P1,4,5) receptor modulator**, which reduces **lymphocyte trafficking** and inflammation. It has previously shown efficacy in other immune-mediated diseases, such as **ulcerative colitis**. --- ### **Trial Design** - **Type**: Randomized, double-blind, placebo-controlled phase 2 study. - **Duration**: Conducted between 2020–2022. - **Locations**: 64 sites across five countries. - **Participants**: 108 adults aged 18–65 years with **histologically active EoE** (≥15 eosinophils per high-power field [eos/hpf] and ≥2 dysphagia episodes per week). - **Groups**: - **41 patients** received etrasimod 2 mg. - **39 patients** received etrasimod 1 mg. - **28 patients** received placebo. --- ### **Baseline Characteristics** - Patients had a **mean disease duration** of 4–5 years. - Many had prior therapies: ~60% had used corticosteroids, ~40% used proton pump inhibitors (PPI). - High disease activity was noted: - **Mean Dysphagia Symptom Questionnaire (DSQ)** score: ~33. - **Peak eosinophil count (PEC)**: ~110 eos/hpf. - **Endoscopic Reference Score (EREFS)**: ~3.7. --- ### **Primary Endpoint** - **Week 16:** Reduction in **peak eosinophil count (PEC)**: - **Etrasimod 2 mg**: –58.4% reduction (**p=0.010 vs placebo**). - **Etrasimod 1 mg**: –39.4% reduction (**p=0.29 vs placebo**). - **Placebo**: –21.5% reduction. - The 2 mg dose demonstrated **significant efficacy** in reducing eosinophilia compared to placebo. --- ### **Key Efficacy Outcomes** 1. **Histologic Remission**: - **Week 16**: 22% of patients on **etrasimod 2 mg** achieved histologic remission (**PEC <15 eos/hpf**), compared to **0% on placebo**. - **Week 24**: Remission rates increased to **32%** for the 2 mg group. 2. **Deeper Remission**: - **Week 16**: 22% of patients on **etrasimod 2 mg** achieved deeper remission (**PEC ≤6 eos/hpf**), compared to **0% on placebo**. 3. **Symptom Improvement**: - **Dysphagia Symptom Questionnaire (DSQ)**: Significant improvement at **week 24** in non-dilated patients on **etrasimod 2 mg** (–21.6 vs –9.6 placebo, **p=0.031**). - **Patient Global Impression of Severity (PGI-S)**: Improved significantly with **2 mg** at week 24 (**p=0.012**). 4. **Endoscopic Improvement**: - **EREFS score**: Improved with **etrasimod 2 mg** at week 16 (–1.0, **p=0.014**) and sustained at week 24 (–0.9, **p=0.030**). 5. **Histology Scores**: - Both doses of etrasimod led to significant improvements in **Histologic Scoring System (HSS)** grade and stage at week 24 (**p<0.0001**) and sustained benefits through **week 52**. 6. **Durability**: - Improvements in eosinophilia, histology, and endoscopy were maintained during the **28-week extension phase**, demonstrating **long-term efficacy**. 7. **Rescue Therapy**: - Fewer patients required rescue therapy on **etrasimod** (10%) compared to placebo (18%), indicating better disease control. --- ### **Mechanism of Action** - **Peripheral lymphocyte counts** decreased dose-dependently: - **60% reduction** with etrasimod 2 mg. - **37% reduction** with etrasimod 1 mg (**p<0.0001**). - This is consistent with etrasimod's immune-modulating mechanism of reducing **lymphocyte trafficking**. --- ### **Safety Profile** 1. **Adverse Events (AEs)**: - Treatment-emergent adverse events (TEAEs) occurred in: - **71%** (etrasimod 2 mg). - **69%** (etrasimod 1 mg). - **75%** (placebo). - Most AEs were **mild-to-moderate**, with gastrointestinal events being the most frequent. 2. **Common AEs**: - Nausea, food impaction, and COVID-19 were reported. - No deaths, macular edema, or serious safety signals were observed. 3. **Cardiac Safety**: - Mild bradycardia occurred in two patients on **etrasimod 2 mg** and one on placebo, all resolving without intervention. - This supports a **manageable cardiac risk** profile. 4. **Comparative Tolerability**: - GI-related adverse events were more frequent in **placebo (50%)** than in etrasimod groups (27–33%), indicating **good tolerability** of the drug. --- ### **Clinical Implications** The **VOYAGE trial** demonstrated that **etrasimod 2 mg** provides significant **histologic, endoscopic, and symptomatic improvements** in adults with EoE. These findings establish proof of concept for **oral S1P receptor modulation** as a promising new therapeutic class for EoE. The drug also showed a **favorable safety profile** and long-term durability, making it a potential alternative to existing treatments for this challenging condition.

Retrograde Cricopharyngeal Dysfunction (R-CPD)

**Retrograde Cricopharyngeal Dysfunction (R-CPD)** is a medical condition that prevents individuals from burping due to the inability of the cricopharyngeal muscle (located in the upper esophageal sphincter) to relax and release trapped air. This condition was first formally recognized in 2019 and has since gained attention for its significant impact on patients' quality of life. ### **Key Features of R-CPD:** 1. **Symptoms:** - **Inability to burp:** Patients report never having been able to burp in their lives. - **Severe bloating:** Air trapped in the stomach and esophagus leads to discomfort. - **Chest pain and abdominal discomfort:** Often caused by the buildup of air. - **Excessive flatulence:** As air passes through the digestive system instead of being released through burping. - **Distinctive throat gurgling noises:** Caused by trapped air trying to escape, which is a hallmark symptom of R-CPD. 2. **Demographics:** - Most commonly affects individuals in their 20s to 30s. - Many patients describe the condition as debilitating, with significant physical and emotional distress. 3. **Impact on Quality of Life:** - R-CPD can interfere with daily activities, social interactions, and overall well-being. - Many patients suffer for years before receiving a diagnosis due to the condition's recent recognition. --- ### **Diagnosis:** Diagnosis of R-CPD is straightforward and primarily based on clinical symptoms: - **Key indicators:** The inability to burp combined with throat gurgling noises strongly suggests the condition. - No invasive tests are typically required for diagnosis. --- ### **Treatment Options:** The primary treatment for R-CPD is **botulinum toxin (Botox) injections** into the cricopharyngeal muscle. This procedure relaxes the muscle, allowing trapped air to escape and enabling patients to burp. 1. **Standard Operating Room Method:** - Performed under sedation using an esophagoscope. - Has a high success rate of **90–95%**. - Considered the most reliable and effective option. 2. **Alternative Techniques:** - **Electromyography-guided (EMG) injections:** - A more complex method involving electrical guidance. - Carries a risk of vocal cord paralysis. - **Transnasal fiberoptic injection:** - A newer, office-based procedure performed quickly without sedation. - Can treat multiple patients in a day but has a lower success rate of **around 60%**. --- ### **Prognosis:** - **Long-term outcomes:** Remarkably, most patients experience lasting relief after a single Botox injection. Even when the drug wears off, the body often "learns" to burp, providing sustained improvement. - **Side effects:** Generally mild and temporary, including: - Difficulty swallowing for a short period. - Rare cases of worsened reflux. --- ### **Significance of Recognition:** R-CPD was unrecognized for many years, leaving patients to suffer from unexplained symptoms without effective treatment. Since its formal identification, it is increasingly recognized as a treatable condition, offering hope and relief to those affected. The availability of effective treatments has transformed the outlook for individuals with this condition, significantly improving their quality of life.

Sucrose vs Sucralose – Appetite stimulation

The study highlights key differences between **sucrose (table sugar)** and **sucralose (a common artificial sweetener)** in terms of their effects on appetite and brain activity: ### **Sucrose (Sugar):** - **Appetite Suppression:** Sucrose consumption was associated with **lower hunger levels**. - **Brain Activity:** Sucrose reduced activity in the hypothalamus, the brain’s hunger regulation center. This suggests that sugar may signal satiety more effectively, potentially curbing appetite after consumption. ### **Sucralose (Artificial Sweetener):** - **Appetite Stimulation:** Sucralose **increased hypothalamic activity** compared to sucrose, which is linked to heightened hunger signals. In some individuals, sucralose made them feel hungrier. - **Brain Activity:** Sucralose raised brain activity in the hypothalamus and increased communication between the hypothalamus and brain regions involved in motivation and decision-making. This suggests that sucralose may influence cravings and eating behavior. - **Variable Effects:** The impact of sucralose varied among individuals: - People with **obesity** or **insulin resistance** showed stronger brain responses to sucralose. - **Women** also exhibited heightened sensitivity to sucralose compared to men. ### **Comparison:** - **Sucrose** appears to suppress appetite and reduce hunger-related brain activity, while **sucralose** may stimulate hunger-related brain activity and, in some cases, increase appetite. - Sucralose's effects on hunger and brain activity are more complex and may depend on individual factors such as metabolic health, gender, and body weight. ### **Implications:** The findings suggest that sucralose might not effectively mimic the appetite-regulating properties of sugar and could potentially lead to increased cravings or altered eating behavior in certain individuals. However, the study was short-term, and more research is needed to fully understand the long-term impacts of sucralose on appetite regulation and metabolic health. ### **Expert Recommendations:** Given the potential appetite-stimulating effects of sucralose and the health risks associated with excessive sugar consumption, experts currently recommend: - Limiting both sugar and artificial sweeteners. - Reducing overall sweetener use to support better metabolic health and avoid potential disruptions in hunger regulation.